Targeting IGF2BP2 alleviates high fat diet aggravated Alzheimer’s disease by inhibiting ferroptosis

Our findings identify IGF2BP2 as a key mediator linking HFD-induced metabolic dysfunction to AD progression via m6A modification and ferroptosis. Targeting IGF2BP2 may represent a promising therapeutic strategy for AD patients with metabolic comorbidities.